Bone mass density testing the society of

This preview shows page 7 - 9 out of 12 pages.

Bone Mass Density TestingThe society of obstetricians and gynaecologist of Canada recommend that all adults older than 50years of age be assessed for the presence of minor and major risk factors for osteoporosis. It isstrongly recommended that any adult over the age of 50, with one of the following characteristicsundergo bone mass density testing: An age of 65 years or older, or 1 or more of the following
clinical risk factors for fracture; fragility fractures after the age of 40, a family history ofosteoporotic fracture, the use of high dose systemic glucocorticoid therapy for 3 month or longer,current smoking and high alcohol intake, low body weight, rheumatoid arthritis, or any otherdisorder of pharmacotherapy strongly associated with a risk of osteoporosis.Adults under the age of 50 should also undergo bone mass density testing if a history of fragilityfractures, premature menopause, primary hyperparathyroidism, hypogonadism or any otherdisorder or pharmacotherapy strongly associated with osteoporosis is identified.Bone mass density test are performed using dual energy x-ray absorptiometry. The test, whichscans the lumbar region and one hip, takes about 10 minutes to perform, features low radiationexposure and is a test with a high sensitivity for the diagnosis of osteoporosis.If a client’s bone mass density is found to be within normal range, and the client is deemed atlow risk for fracture, repeated testing should be performed every 5 years to monitor for changesin bone mass density. To maintain bone health, 1200mg of elemental calcium from dietary andsupplemental sources as well as supplementation with 800—to 2000 international units ofvitamin D is recommended for all postmenopausal women.If a client is deemed at moderate risk for fracture, preventative strategies such as lifestylechanges as well as pharmacotherapy, depending on the patient’s risk factors, should be initiated.In cases of severe bone mass density loss, pharmacological treatment for osteoporosis is requiredto increase bone mass density and mediate the high risk of fragility fracture. In cases of moderateand high risk for fracture, bone mass density test should be repeated every 1-3 years to reassessesrisk.Pharmacological Treatment of OsteoporosisWhile routine calcium and vitamin D supplementation alone is insufficient to prevent fractures inthose with osteoporosis, and therefore cannot be used as the sole means of therapy for thisdisease, supplementation with elemental calcium and vitamin D is still recommended as adjuncttherapy to the main pharmacological interventions for osteoporosis.Hormone replacement therapyDue to the associated risks of breast cancer, heart disease and stroke, hormone therapy is onlyrecommended for women with moderate to severe symptoms of menopause. Hormone therapyshould not be prescribed solely for the prevention and treatment of osteoporosis, but rathershould be considered a positive secondary benefit of hormone therapy for the treatment of

Upload your study docs or become a

Course Hero member to access this document

Upload your study docs or become a

Course Hero member to access this document

End of preview. Want to read all 12 pages?

Upload your study docs or become a

Course Hero member to access this document

Term
Fall
Professor
dr. culver
Tags
postmenopausal osteoporosis

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture